Hyperlipidemia

Management with proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors

Muhammed Shahreyar, Salem A. Salem, Mannu Nayyar, Lekha George, Nadish Garg, Santhosh Koshy

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Coronary artery disease is the leading cause of death in United States. Hyperlipidemia is an independent and potentially reversible risk factor for coronary artery disease. The 3-hydroxy-3-methylglutaryl-coen-zyme A reductase inhibitors, collectively known as statins, have been the mainstay of pharmacologic therapy. Their availability, ease of administration, low cost, and strong evidence behind safety and efficacy makes them one of the most widely prescribed lipid-lowering agents. However, some patients may be intolerant to statins, and few others suffer from very high serum levels of cholesterol in which statin therapy alone or in combination with other cholesterol-lowering agents is insufficient in reducing serum lipid levels to achieve desired levels. In 2015, the Food and Drug Administration approved a new family of lipid-lowering agents, collectively known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 inhibitors are biologically active molecules that decrease serum low-density lipoprotein cholesterol compared with statin therapy alone. They serve as an alternative to statins for patients who are intolerant to statin or as supplemental therapy in those patients for whom lower levels in serum low-density lipoprotein cholesterol are not achieved by statins alone. This article discusses PCSK9 inhibitors, their mechanism of action, indications, efficacy, safety, costs and limitations.

Original languageEnglish (US)
Pages (from-to)628-634
Number of pages7
JournalJournal of the American Board of Family Medicine
Volume31
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Serum
Lipids
LDL Cholesterol
Coronary Artery Disease
Safety
Costs and Cost Analysis
United States Food and Drug Administration
Therapeutics
Proprotein Convertase 9
Hypercholesterolemia
Cause of Death
Oxidoreductases
Cholesterol

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Family Practice

Cite this

Hyperlipidemia : Management with proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors. / Shahreyar, Muhammed; Salem, Salem A.; Nayyar, Mannu; George, Lekha; Garg, Nadish; Koshy, Santhosh.

In: Journal of the American Board of Family Medicine, Vol. 31, No. 4, 01.07.2018, p. 628-634.

Research output: Contribution to journalReview article

@article{6d590979af1e4f40b606438aa1ac190a,
title = "Hyperlipidemia: Management with proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors",
abstract = "Coronary artery disease is the leading cause of death in United States. Hyperlipidemia is an independent and potentially reversible risk factor for coronary artery disease. The 3-hydroxy-3-methylglutaryl-coen-zyme A reductase inhibitors, collectively known as statins, have been the mainstay of pharmacologic therapy. Their availability, ease of administration, low cost, and strong evidence behind safety and efficacy makes them one of the most widely prescribed lipid-lowering agents. However, some patients may be intolerant to statins, and few others suffer from very high serum levels of cholesterol in which statin therapy alone or in combination with other cholesterol-lowering agents is insufficient in reducing serum lipid levels to achieve desired levels. In 2015, the Food and Drug Administration approved a new family of lipid-lowering agents, collectively known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 inhibitors are biologically active molecules that decrease serum low-density lipoprotein cholesterol compared with statin therapy alone. They serve as an alternative to statins for patients who are intolerant to statin or as supplemental therapy in those patients for whom lower levels in serum low-density lipoprotein cholesterol are not achieved by statins alone. This article discusses PCSK9 inhibitors, their mechanism of action, indications, efficacy, safety, costs and limitations.",
author = "Muhammed Shahreyar and Salem, {Salem A.} and Mannu Nayyar and Lekha George and Nadish Garg and Santhosh Koshy",
year = "2018",
month = "7",
day = "1",
doi = "10.3122/jabfm.2018.04.170447",
language = "English (US)",
volume = "31",
pages = "628--634",
journal = "Journal of the American Board of Family Medicine",
issn = "1557-2625",
publisher = "American Board of Family Medicine",
number = "4",

}

TY - JOUR

T1 - Hyperlipidemia

T2 - Management with proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors

AU - Shahreyar, Muhammed

AU - Salem, Salem A.

AU - Nayyar, Mannu

AU - George, Lekha

AU - Garg, Nadish

AU - Koshy, Santhosh

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Coronary artery disease is the leading cause of death in United States. Hyperlipidemia is an independent and potentially reversible risk factor for coronary artery disease. The 3-hydroxy-3-methylglutaryl-coen-zyme A reductase inhibitors, collectively known as statins, have been the mainstay of pharmacologic therapy. Their availability, ease of administration, low cost, and strong evidence behind safety and efficacy makes them one of the most widely prescribed lipid-lowering agents. However, some patients may be intolerant to statins, and few others suffer from very high serum levels of cholesterol in which statin therapy alone or in combination with other cholesterol-lowering agents is insufficient in reducing serum lipid levels to achieve desired levels. In 2015, the Food and Drug Administration approved a new family of lipid-lowering agents, collectively known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 inhibitors are biologically active molecules that decrease serum low-density lipoprotein cholesterol compared with statin therapy alone. They serve as an alternative to statins for patients who are intolerant to statin or as supplemental therapy in those patients for whom lower levels in serum low-density lipoprotein cholesterol are not achieved by statins alone. This article discusses PCSK9 inhibitors, their mechanism of action, indications, efficacy, safety, costs and limitations.

AB - Coronary artery disease is the leading cause of death in United States. Hyperlipidemia is an independent and potentially reversible risk factor for coronary artery disease. The 3-hydroxy-3-methylglutaryl-coen-zyme A reductase inhibitors, collectively known as statins, have been the mainstay of pharmacologic therapy. Their availability, ease of administration, low cost, and strong evidence behind safety and efficacy makes them one of the most widely prescribed lipid-lowering agents. However, some patients may be intolerant to statins, and few others suffer from very high serum levels of cholesterol in which statin therapy alone or in combination with other cholesterol-lowering agents is insufficient in reducing serum lipid levels to achieve desired levels. In 2015, the Food and Drug Administration approved a new family of lipid-lowering agents, collectively known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 inhibitors are biologically active molecules that decrease serum low-density lipoprotein cholesterol compared with statin therapy alone. They serve as an alternative to statins for patients who are intolerant to statin or as supplemental therapy in those patients for whom lower levels in serum low-density lipoprotein cholesterol are not achieved by statins alone. This article discusses PCSK9 inhibitors, their mechanism of action, indications, efficacy, safety, costs and limitations.

UR - http://www.scopus.com/inward/record.url?scp=85049900959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049900959&partnerID=8YFLogxK

U2 - 10.3122/jabfm.2018.04.170447

DO - 10.3122/jabfm.2018.04.170447

M3 - Review article

VL - 31

SP - 628

EP - 634

JO - Journal of the American Board of Family Medicine

JF - Journal of the American Board of Family Medicine

SN - 1557-2625

IS - 4

ER -